Patents by Inventor Larry W. McLaughlin

Larry W. McLaughlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Turn over probes and use thereof for nucleic acid detection
    Patent number: 7968289
    Abstract: The invention provides turnover probes for use in a variety of detection assays, for example, nucleic acid detection assays. In addition, the invention provides assays, for example, nucleic acid detection assays, using such turnover probes.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: June 28, 2011
    Assignee: Ensemble Therapeutics Corporation
    Inventors: James M. Coull, Lawrence A. Haff, Joshua A. Bittker, Xiaoyu Li, Larry W. McLaughlin
  • Turn Over Probes and Use Thereof for Nucleic Acid Detection
    Publication number: 20090280477
    Abstract: The invention provides turnover probes for use in a variety of detection assays, for example, nucleic acid detection assays. In addition, the invention provides assays, for example, nucleic acid detection assays, using such turnover probes.
    Type: Application
    Filed: May 3, 2006
    Publication date: November 12, 2009
    Inventors: James M. Coull, Lawrence A. Haff, Joshua A. Bittker, Xiaoyu Li, Alexander F. Rosenberg, Larry W. McLaughlin
  • Selective anti-viral nucleoside chain terminators
    Patent number: 6914052
    Abstract: The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3?-dideoxy-?-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an “O2 carbonyl”, that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: July 5, 2005
    Assignee: The Trustees of Boston College
    Inventors: Larry W. McLaughlin, Andrew W. Fraley, DongLi Chen, Tao Lan
  • Selective anti-viral nucleoside chain terminators
    Publication number: 20030100759
    Abstract: The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3 ′-dideoxy-&bgr;-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an “O2 carbonyl”, that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.
    Type: Application
    Filed: March 13, 2002
    Publication date: May 29, 2003
    Inventors: Larry W. McLaughlin, Andrew W. Fraley, DongLi Chen, Tao Lan